<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02514525</url>
  </required_header>
  <id_info>
    <org_study_id>CP-0011</org_study_id>
    <nct_id>NCT02514525</nct_id>
  </id_info>
  <brief_title>Multi-center Clinical Study to Evaluate the C2 CryoBalloon Focal Ablation System</brief_title>
  <acronym>ColdPlayIII</acronym>
  <official_title>Multi-center Clinical Study to Evaluate the C2 CryoBalloon Focal Ablation System for the Treatment of Patients With Previously Untreated Dysplastic Barrett's Epithelium</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>C2 Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>C2 Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the efficacy and safety of the CryoBalloon Focal Ablation System for the
      treatment of previously-untreated (&quot;treatment naïve&quot;) Barrett's Esophagus (BE)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Coldplay III is a multi-center, prospective study that will provide evidence of the efficacy
      and safety of the System in treatment of patients with previously untreated (treatment naïve)
      low grade dysplasia (LGD) or high grade dysplasia (HGD) BE. Subjects may have a maximum of
      five (5) ablation treatment sessions during their 12 months of study participation to achieve
      complete eradication of their dysplastic BE and intestinal metaplasia. As many ablations as
      needed to treat the dysplastic areas are allowed in each treatment session at the discretion
      of the investigator.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2016</start_date>
  <completion_date type="Anticipated">May 2021</completion_date>
  <primary_completion_date type="Anticipated">May 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of serious, CryoBalloon Ablation System-related adverse events</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of patients with baseline LGD who have complete eradication of all dysplasia</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>percentage of patients with baseline HGD who have complete eradication of all dysplasia</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>percentage of all treated patients who have complete eradication of all dysplasia (CE-D)</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects with complete eradication of all esophageal intestinal metaplasia (CE-IM)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects with progression of dysplasia from LGD to HGD or esophageal cancer, or progression of HGD to cancer</measure>
    <time_frame>12 months</time_frame>
    <description>For Baseline LGD and HGD subjects: progression of dysplasia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of all treatment-related and all serious, non-treatment-related adverse events</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of post procedure chest discomfort events / Pain score &gt;0 and &lt;5</measure>
    <time_frame>Day 1</time_frame>
    <description>(scored on a 0-10 visual analog pain scale)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of post procedure chest discomfort events / Pain score ≥5 and requiring narcotic analgesic</measure>
    <time_frame>Day 7</time_frame>
    <description>(scored on a 0-10 visual analog pain scale)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean and Median Pain score on Day 1 post procedure</measure>
    <time_frame>Day 1</time_frame>
    <description>(scored on a 0-10 visual analog pain scale)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean and Median Pain score on Day 7 post procedure</measure>
    <time_frame>Day 7</time_frame>
    <description>(scored on a 0-10 visual analog pain scale)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of (CE-D) and all esophageal (CE-IM) will be reported as a percentage of all subjects enrolled, and stratified by baseline dysplasia grade</measure>
    <time_frame>24 and 36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of CryoBalloon ablation treatments required to achieve CE-D or CE-IM</measure>
    <time_frame>12 months</time_frame>
    <description>(mean and median)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Barrett Esophagus</condition>
  <arm_group>
    <arm_group_label>CryoBalloon Ablation System</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Cryoablation treatment of patients with previously untreated (treatment naïve) Barrett's epithelium.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CryoBalloon Ablation System</intervention_name>
    <description>CryoBalloon Ablation System, a balloon-based cryotherapy device, provides controlled ablation for the treatment of BE. Deployed through the working channel of an endoscope, the Balloon is simultaneously inflated and cooled with an inert cryogen (nitrous oxide) delivered from the handle that ablates the BE cells upon contact with the esophagus.</description>
    <arm_group_label>CryoBalloon Ablation System</arm_group_label>
    <other_name>CryoBalloon Focal Ablation System</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Low- or high-grade non-nodular, previously untreated (&quot;treatment naïve&quot;) dysplastic
             BE, confirmed by histopathological analysis. If nodular BE or Intramuscosal Cancer
             (ImCA) is identified during patient screening, this may be treated with Endoscopic
             Mucosal Resection (EMR) ≥6 weeks prior to treatment under this protocol. If previous
             EMR was performed, follow-up endoscopy must be negative for nodular BE. Patients with
             ImCA must be at low risk for recurrence, confirmed by EMR pathology results negative
             for positive margin, poorly differentiated carcinoma, and lymphovascular invasion.

          -  BE length ≤6cm excluding visible BE islands, and Prague Classification C ≥0 / M ≥1

          -  Older than 18 years of age at time of consent

          -  Operable per institution's standards

          -  Provides written informed consent on the approved informed consent form

          -  Willing and able to comply with study requirements for follow-up

        Exclusion Criteria:

          -  Non-dysplastic or indefinite for dysplasia BE, confirmed by histopathological analysis

          -  Esophageal stenosis/stricture preventing advancement of a therapeutic endoscope
             (patients may have the stenosis/stricture dilated and then be treated with CryoBalloon
             ablation under this protocol at a subsequent procedure ≥2 weeks later)

          -  Symptomatic untreated strictures

          -  Any endoscopically-visualized abnormalities such as ulcers, masses or nodules.
             Neoplastic nodules must first be treated with EMR ≥6 weeks prior to planned treatment
             under this protocol.

          -  History of esophageal cancer more extensive than T1a or not meeting criteria for low
             risk of recurrence (confirmed by EMR pathology results negative for positive margin,
             poorly differentiated carcinoma, and lymphovascular invasion)

          -  History of esophageal varices

          -  Large (&gt;4cm) hiatal hernia

          -  Prior distal esophagectomy

          -  Any clinical or histological suspicion of esophageal adenocarcinoma invading into the
             submucosa by endoscopic mucosal resection (EMR), or confirmed T1a cancer with positive
             deep margin by EMR

          -  Active esophagitis grade B or higher

          -  Severe medical comorbidities precluding endoscopy

          -  Uncontrolled coagulopathy

          -  Pregnant or planning to become pregnant during period of study participation

          -  Patient refuses or is unable to provide written informed consent

          -  Life expectancy ≤3 years, as judged by the site investigator

          -  General poor health, multiple co-morbidities placing the patient at risk or otherwise
             unsuitable for trial participation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marcia Canto, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marcia Wachna, RN</last_name>
    <phone>650-996-2183</phone>
    <email>marcia@c2therapeutics.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marcia Canto, MD</last_name>
    <phone>410-964-5199</phone>
    <email>mcanto@jhmi.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UC Irvine</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eva Maurer</last_name>
      <phone>714-456-2215</phone>
      <email>emaurer@uci.edu</email>
    </contact>
    <investigator>
      <last_name>Kenneth Chang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sarasota Memorial Hospital</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Diane Barrett</last_name>
      <phone>941-365-6556</phone>
      <email>Diane.Barrett@fdhs.com</email>
    </contact>
    <investigator>
      <last_name>F. Scott Corbett, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kianoush Donboli</last_name>
      <phone>773-926-8490</phone>
      <email>kdonboli@medicine.bsd.uchicago.edu</email>
    </contact>
    <investigator>
      <last_name>Irving Waxman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>John Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hilary Cosby, RN</last_name>
      <phone>410-502-2893</phone>
      <email>hcosby1@jhmi.edu</email>
    </contact>
    <investigator>
      <last_name>Mimi Canto, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michele Johnson</last_name>
      <phone>507-293-5307</phone>
      <phone_ext>3-5307</phone_ext>
      <email>johnson.michele@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Prasad G. Iyer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwell Health</name>
      <address>
        <city>Manhasset</city>
        <state>New York</state>
        <zip>11030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Molly Stewart, BS</last_name>
      <phone>516-321-8017</phone>
      <email>mstewart8@northwell.edu</email>
    </contact>
    <investigator>
      <last_name>Arvind Trindad, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New York Presbyterian Hospital-Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Garofano</last_name>
      <phone>212-304-5686</phone>
      <email>rfg2115@cumc.columbia.edu</email>
    </contact>
    <investigator>
      <last_name>Julian Abrams, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of North Carolina School of Medicine</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yaa Ofori-Marfoh</last_name>
      <phone>919-843-5884</phone>
      <email>yaa_ofori-marfoh@med.unc.edu</email>
    </contact>
    <investigator>
      <last_name>Nicholas J. Shaheen, MD, MPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospitals Cleveland Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wendy Brock, RN</last_name>
      <phone>216-844-3853</phone>
      <email>wendy.brock@UHhospitals.org</email>
    </contact>
    <investigator>
      <last_name>Amitabh Chak, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Geisinger Medical Center</name>
      <address>
        <city>Danville</city>
        <state>Pennsylvania</state>
        <zip>17822</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle Kopfinger, RN</last_name>
      <phone>570-214-5420</phone>
      <email>mckopfinger@geisinger.edu</email>
    </contact>
    <investigator>
      <last_name>David Diehl, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mike Matthews</last_name>
      <phone>215-503-2545</phone>
      <email>Michael.Matthews@jefferson.edu</email>
    </contact>
    <investigator>
      <last_name>Anthony Infantolino, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 31, 2015</study_first_submitted>
  <study_first_submitted_qc>July 31, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 3, 2015</study_first_posted>
  <last_update_submitted>April 25, 2018</last_update_submitted>
  <last_update_submitted_qc>April 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Barrett Esophagus</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Individual participant data will not be shared.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

